Off-label use of medical products in radiation therapy: Summary of the Report of AAPM Task Group No. 121

Medical Physics

Volumn 37, Issue 5, 2010, Pages 2300-2311

  Thomadsen, Bruce R ^a   Heaton, H Thompson ^b   Jani, Shirish K ^c   Masten, Jeffery P ^d   Napolitano, Mary E ^e   Ouhib, Zoubir ^f   Reft, Chester S ^g   Rivard, Mark J ^h   Robin, T Tydings ⁱ   Subramanian, Manny ^j   Suleiman, Orhan H ^k  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b Sharp Memorial Hospital ^*

^c SHARP MEMORIAL HOSPITAL   (United States)

^d RAPID CITY REGIONAL HOSPITAL   (United States)

^e Elekta AB   (Sweden)

^f Lynn Regional Cancer Center   (United States)

^g UNIVERSITY OF CHICAGO   (United States)

^h TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ Theragenics Corporation   (United States)

^j Best Medical International Inc   (United States)

^k CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

more..

Author keywords

FDA; Off label use; Radiotherapy

Indexed keywords

COMMERCE; COPYRIGHTS; LAWS AND LEGISLATION; MANUFACTURE; MARKETING; RADIOTHERAPY;

BIOLOGICAL PRODUCTS; CLINICAL SITUATIONS; COMMERCIAL PRODUCTS; FOOD AND DRUG ADMINISTRATION; LEGAL IMPLICATIONS; LICENSE AGREEMENTS; MEDICAL PHYSICISTS; OFF-LABEL USE;

DRUG PRODUCTS;

EID: 77952414080     PISSN: 00942405     EISSN: None     Source Type: Journal    
DOI: 10.1118/1.3392286     Document Type: Article

References (86)

1. G. P. Glasgow, " Nuclear Regulatory Commission regulatory status of approved intravascular brachytherapy systems.," Cardiovasc. Radiat. Med. 3, 60-66 (2002). 10.1016/S1522-1865(02)00151-8 1522-1865 (Pubitemid 35461903)
2. See, for example, Klein v. Biscup, 673 N.E.2d 225, 231 (Ohio Ct. App.), appeal denied, 667 N.E.2d 987 (Ohio 1996).
3. See, e.g., Rhone-Poulenc Rorer Pharm., Inc, v. Marion Merrell Dow, Inc., 93 F.3d 511, 514 n.3 (8th Cir., 1996), Bristol Myers Squibb Co. v. Shalala, 91 F.3d 1493 (D.C. Cir. 1996); Weaver v. Reagen, 886 F.2d 194, 198 (8th Cir. 1989); United States v. An Article of DeviceDiapulse, 768 F.2d 826, 832 (7th Cir. 1985); Schlessing v. United States, 239 F.2d 885, 886 (9th Cir. 1956); Washington Legal Found., 880 F. Supp. at 28, n.1.; United States v. Evers, 453 F. Supp. 1141, 1149-1150 (M.D. Ala. 1978), aff'd, 643 F.2d 1043, 1052-53 (5th Cir. 1981); FTC v. Simeon Management Corp., 391 F. Supp. 697, 706 (N.D. Cal. 1975), aff'd, 532 F.2d 708 (9th Cir. 1976); Upjohn Co. v. MacMurdo, 562 So.2d 680, 683 (Fla. 1990); Jones v. Petland Orlando Store, 622 So.2d 1114, 1115 (Fla Dist. Ct. App. 1993); Haynes v, Baton Rouge Gen. Hosp. 298 So.2d 149, 153 (La. Ct. App. 1974), writ denied, 302 So.2d 33 (La. 1974); Peter Hutt, Regulation of the Practice of Medicine Under the Pure Food & Drug Laws, 33 Food & Drug Officials Q. Bull. 7-11 (1969).
4. J. M. Beck, " FDA: Off-label use and informed consent: Debunking myths and misconceptions.," Food and Drug Law Journal 53, 71-104 (1998).
5. M. D. Abeloff, " Off-label uses of anticancer drugs. Letter to the Editor.," JAMA, J. Am. Med. Assoc. JAMAAP 0098-7484 267, 2473-2474 (1992). 10.1001/jama.267.18.2473
6. Proctor v. Davis, 682 N.E.2d 1203, 1213 (Ill. App. 1997).
7. See, e.g., Washington Legal Foundation v. Kessler, 880 F. Supp. 26, 28 n. 1(D.D.C. 1995). Off-label can mean many things. "[U]sing an approved drug to treat a disease that is not indicated on its label, but is closely related to an indicated disease, treating unrelated, unindicated diseases, and treating the indicated disease but varying from the indicated dosage, regimen, or patient population may all be considered off-label use." W. Christopher, " Off-label drug prescription: Filling the regulatory vacuum.," 48 Food and Drug Law Journal, pp. 247-262 (1993) (footnotes omitted)].
8. See, e.g., J. M. Beck and E. D. Azari, " FDA: Off-label use, and informed consent: Debunking myths and misconceptions.," Food and Drug Law Journal 53, 71-104 (1998); Femrite v. Abbot Northwestern Hospital, 568 N.W.2d 535 at 539 n4 (Minn. Ct. App. 1997); Klein v. Biscup, 673 N.E.2d 225, 231 (Ohio Ct. App.), appeal denied, 667 N.E.2d 987 (Ohio 1996); In re Orthopedic Bone Screw Products Liability Litigation, MDL No. 1014, 1996 WL 107556 at 3 (E.D. Pa. Mar. 8, 1996) ("the decision whether or not to use a drug for an off-label purpose is a matter of medical judgment, not of regulatory approval") (citation and quotation marks omitted). The FDCA was "not intended as a medical practices act and [did] not interfere with the practice of the healing art." S.R. No. 361, 74th Cong., 1st Sess. 3 (1935).
9. P. S. Spivak, " Off-label promotion under scrutiny by DOJ, The Department of Justice is aggressively pursuing healthcare fraud allegations.," Genetic Engineering and Biotechnology News (GEN), 1 June 2008, Vol. 1, No. 11.
10. The Wall Street Journal, Front Page, 19 November 2008, Vol. CCLII, No.120.
11. See http://www.fda.gov/RegulatoryInformation/Guidances/ucm125126.htm for the article " Good reprint practices for the distribution of medical journal articles and medical or scientific reference publications on unapproved new uses of approved drugs and approved or cleared medical devices.," (last accessed 3 November 2009).
12. Department of Health and Human Services, Food and Drug Administration, Office of the Commissioner, Office of Policy, " Guidance for industry on good reprint practices for the distribution of medical journal articles and medical or scientific reference publications on unapproved new uses of approved drugs and approved or cleared medical devices: Availability.," Fed. Regist. FEREAC 0097-6326 74 (8), 1694-1695 (2009).
13. American Academy of Pediatrics, Committee on Drugs, " Uses of drugs not described in the package insert: Off-label uses.," Pediatrics PEDIAU 0031-4005 110, 181-183 (2002). 10.1542/peds.110.1.181 (Pubitemid 34742660)
14. Committee on Labor and Human Resources, " Off-label drugs: Reimbursement policies constrain physicians in their choice of cancer therapies.," Report to the Chairman, US Senate Publication No. GA/PEMD 91-14, September 1991.
15. H. J. DeMonaco, A. Ali, and E. von Hippel, " The major role of clinicians in the discovery of off-label drug therapies.," Pharmacotherapy ZZZZZZ 0277-0008 26, 323-332 (2006). 10.1592/phco.26.3.323 (Pubitemid 43334671)
16. ® film.," Med. Phys. MPHYA6 0094-2405 31, 201-207 (2004). 10.1118/1.1637733 (Pubitemid 38235390)
17. S. K. Jani, G. Long, G. B. Huppe, V. Massullo, P. Tripuraneni, and P. S. Teirstein, " Cordis Checkmate: Manually loaded iridium-192 ribbon.," in Vascular Brachytherapy, 3rd ed., edited by, R. Waksman, (Futura, Armonk, 2002), pp. 707-716.
18. K. W. Elliot, R. P. Walsh, and R. diMonda, " Novoste Beta-Cath system: Intracoronary radiation with strontium 90.," in Vascular Brachytherapy, 3rd ed., edited by, R. Waksman, (Futura, Armonk, 2002), pp. 717-728.
19. D. M. Duggan, C. W. Coffey II, J. L. Lobdell, and M. C. Schell, " Radiochromic film dosimetry of a high dose rate beta source for intravascular brachytherapy.," Med. Phys. MPHYA6 0094-2405 26, 2461-2464 (1999). 10.1118/1.598814
20. M. Piessens, N. Reynaert, J. Potempa, H. Thierens, W. Wijns, and L. Verbeke, " Dose distributions for Y 90 intravascular brachytherapy sources used with balloon catheters.," Med. Phys. MPHYA6 0094-2405 29, 1562-1571 (2002). 10.1118/1.1488604 (Pubitemid 34774589)
21. D. E. Roa, H. Song, N. Yue, F. d'Errico, and R. Nath, " Dosimetric characteristics of the Novoste Beta-Cath S 90 r/Y source trains at submillimeter distances.," Med. Phys. MPHYA6 0094-2405 31, 1269-1276 (2004). 10.1118/1.1697695 (Pubitemid 38656802)
22. L. A. Buckley, B. R. Thomadsen, and L. A. DeWerd, " The water-equivalence of phantom materials for S 90 r- Y 90 beta particles.," Med. Phys. MPHYA6 0094-2405 28, 1010-1015 (2001). 10.1118/1.1376176
23. R. Waksman, D. P. Faxon, and S. F. Liprie, " The Angiorad Gamma wire system.," in Vascular Brachytherapy, 3rd ed., edited by, R. Waksman, (Futura, Armonk, 2002), pp. 771-778.
24. A. E. Raizner, G. L. Kaluza, R. V. Caffee, and A. J. Bradshaw, " The Guidant coronary source wire system.," in Vascular Brachytherapy, 3rd ed., edited by, R. Waksman, (Futura, Armonk, 2002), pp. 737-752.
25. T. D. Bohm, F. A. Mourtada, and R. K. Das, " Dose rate table for a P 32 intravascular brachytherapy source from Monte Carlo calculations.," Med. Phys. MPHYA6 0094-2405 28, 1770-1775 (2001). 10.1118/1.1384459 (Pubitemid 32783222)
26. F. A. Mourtada, C. G. Soares, S. M. Seltzer, and S. H. Lott, " Dosimetry characterization of P 32 catheter-based vascular brachytherapy source wire.," Med. Phys. MPHYA6 0094-2405 27, 1770-1776 (2000). 10.1118/1.1286551 (Pubitemid 30666352)
27. F. Mourtada, C. G. Soares, S. M. Seltzer, P. M. Bergstrom, Jr., J. M. Fernandez-Verea, J. Asenjoa, and S. H. Lott, " Dosimetry characterization of a P 32 source wire used for intravascular brachytherapy with automated stepping.," Med. Phys. MPHYA6 0094-2405 30, 959-971 (2003). 10.1118/1.1567832 (Pubitemid 36578700)
28. F. Mourtada, C. G. Soares, and J. L. Horton, " A segmented P 32 source Monte Carlo model to derive AAPM TG-60 dosimetric parameters used for intravascular brachytherapy.," Med. Phys. MPHYA6 0094-2405 31, 602-608 (2004). 10.1118/1.1646651 (Pubitemid 38381024)
29. J. Torres, M. J. Buades, J. F. Almansa, R. Guerrero, and A. M. Lallena, " Dosimetry characterization of P 32 intravascular brachytherapy source wires using Monte Carlo codes PENELOPE and GEANT4.," Med. Phys. MPHYA6 0094-2405 31, 296-304 (2004). 10.1118/1.1637970 (Pubitemid 38235399)
30. R. Wang and X. Allen Li, " Monte Carlo characterization of a P 32 source for intravascular brachytherapy.," Med. Phys. MPHYA6 0094-2405 28, 1776-1795 (2001). 10.1118/1.1388222 (Pubitemid 32783223)
31. Z. Xu, P. R. Almond, and J. O. Deasy, " The dose distribution produced by a P 32 source for endovascular irradiation.," Int. J. Radiat. Oncol., Biol., Phys. IOBPD3 0360-3016 36, 933-939 (1996). 10.1016/S0360-3016(96) 00300-8 (Pubitemid 27008610)
32. Z. Xu, L. E. Reinstein, G. Yang, S. Pai, G. Gluckman, and P. R. Almond, " The investigation of P 32 wire for catheter-based endovascular irradiation.," Med. Phys. MPHYA6 0094-2405 24, 1788-1792 (1997). 10.1118/1.597944 (Pubitemid 27495915)
33. Y. Popowski, V. Verin, I. Papirov, P. Nouet, M. Rouzaud, E. Grob, M. Schwager, P. Urban, W. Rutishauser, and J. M. Kurtz, " Intra-arterial Y 90 brachytherapy: Preliminary dosimetric study using a specially modified angioplasty balloon.," Int. J. Radiat. Oncol., Biol., Phys. IOBPD3 0360-3016 33, 713-717 (1995). 10.1016/0360-3016(95)00259-2
34. Y. Popowski, V. Verin, and P. Urban, " Endovascular Β -irradiation after percutaneous transluminal coronary angioplasty.," Int. J. Radiat. Oncol., Biol., Phys. IOBPD3 0360-3016 36, 841-845 (1996). 10.1016/S0360-3016(96)00411-7 (Pubitemid 27008598)
35. Y. Popowski, V. Verin, M. Schwager, P. Nouet, I. Papirov, M. Rouzaud, P. Urban, J. R. Landis, W. Rutishauser, and J. M. Kurtz, " A novel system for intracornary Β -irradiation: Description and dosimetric results.," Int. J. Radiat. Oncol., Biol., Phys. IOBPD3 0360-3016 36, 923-931 (1996). 10.1016/S0360-3016(96)00409-9 (Pubitemid 27008609)
36. U. O. Häfeli, W. K. Roberts, D. S. Meier, J. P. Ciezki, G. J. Pauer, E. J. Lee, and M. S. Weinhous, " Dosimetry of a W-188/Re-188 beta line source for endovascular brachytherapy.," Med. Phys. MPHYA6 0094-2405 27, 668-675 (2000). 10.1118/1.598928 (Pubitemid 30227043)
37. D. R. Schaart, " The scaling method applied to beta particle line sources with a finite diameter.," Med. Phys. MPHYA6 0094-2405 29, 2682-2686 (2002). 10.1118/1.1513567 (Pubitemid 35375467)
38. C. W. Coffey II and D. M. Duggan, " The calculation and measurement of radiation dose surrounding radioactive stents: The effects of radionuclide selection and stent design on dosimetric results.," in Vascular Brachytherapy, 3rd ed., edited by, R. Waksman, (Futura, Armonk, 2002), pp. 349-378.
39. C. Janicki, D. M. Duggan, C. W. Coffey, D. R. Fischell, and T. A. Fischell, " Radiation dose from a phosphorous-32 impregnated wire mesh vascular stent.," Med. Phys. MPHYA6 0094-2405 24, 437-445 (1997). 10.1118/1.597910 (Pubitemid 27133489)
40. C. Janicki, D. M. Duggan, A. Gonzalez, C. W. Coffey II, and D. A. Rahdert, " Dose model for a beta-emitting stent in a realistic artery consisting of soft tissue and plaque.," Med. Phys. MPHYA6 0094-2405 26, 2451-2460 (1999). 10.1118/1.598813
41. J. Weinberger and F. F. Knap, Jr., " Liquid-filled balloons for coronary brachytherapy.," in Vascular Brachytherapy, 3rd ed., edited by, R. Waksman, (Futura, Armonk, 2002), pp. 753-770.
42. H. I. Amols, L. E. Reinstein, and J. Weinberger, " Dosimetry of a radioactive coronary balloon dilation catheter for treatment of neointimal hyperplasia.," Med. Phys. MPHYA6 0094-2405 23, 1783-1788 (1996). 10.1118/1.597761 (Pubitemid 26349791)
43. C. -S. Wuu, P. Schiff, M. J. Maryanski, T. Liu, S. Borzillary, and J. Weinberger, " Dosimetry study of Re-188 liquid balloon for intravascular brachytherapy using polymer gel dosimeters and laser-beam optical CT scanner.," Med. Phys. MPHYA6 0094-2405 30, 132-137 (2003). 10.1118/1.1533749 (Pubitemid 36222848)
44. M. Apple and R. Waksman, " Xenon 133 gas filled balloon.," in Vascular Brachytherapy, 3rd ed., edited by, R. Waksman, (Futura, Armonk, 2002), pp. 787-798.
45. M. Buchbinder, G. Strathearn, and B. Trauthen, " RDX coronary radiation delivery system: Balloon-based radiation therapy.," in Vascular Brachytherapy, 3rd ed., edited by, R. Waksman, (Futura, Armonk, 2002), pp. 799-810.
46. C. Hehrlein, A. Kovacs, G. K. Wolf, N. Yue, and R. Nath, " Balloon catheters impregnated with radioisotopes for the prevention of restenosis.," in Vascular Brachytherapy, 3rd ed., R. Waksman, (Futura, Armonk, 2002), pp. 811-818.
47. F. M. van Kireken and E. Loeffler, " Peripheral vascular brachytherapy using the Nucletron Paris catheter and the microSelectron-HDR afterloader.," in Vascular Brachytherapy, 3rd ed., edited by, R. Waksman, (Futura, Armonk, 2002), pp. 729-736.
48. S. Parikh and D. Nori, " External radiation therapy for patients with arteriovenous dialysis shunts.," in Vascular Brachytherapy, 3rd ed., edited by, R. Waksman, (Futura, Armonk, 2002), pp. 505-524.
49. See http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfTopic/pma/pma. cfm?num=p990036 (Cordis) for Cordis Checkmate system clearance (last accessed 3 November 2009).
50. See http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfTopic/pma/pma. cfm?num=p000018 (Novoste) for Novost Beta-Cath system clearance (last accessed 3 November 2009).
51. See http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfTopic/pma/pma. cfm?num=p000052 (Guidant) for GALILEO intravascular radiotherapy system clearance (last accessed 3 November 2009).
52. D. Baltas, P. Karaiskos, P. Papagiannis, L. Sakelliou, E. Loeffler, and N. Zamboglou, " Beta versus gamma dosimetry close to Ir-192 brachytherapy sources.," Med. Phys. MPHYA6 0094-2405 28, 1875-1882 (2001). 10.1118/1.1395038 (Pubitemid 32899726)
53. M. Bambynek, D. Flühs, U. Quast, D. Wegener, and C. G. Soares, " A high-precision, high-resolution and fast dosimetry system for beta sources applied in cardiovascular brachytherapy.," Med. Phys. MPHYA6 0094-2405 27, 662-667 (2000). 10.1118/1.598927 (Pubitemid 30227042)
54. O. Chibani and X. Allen Li, " IVBTMC: A Monte Carlo dose calculation tool for intravascular brachytherapy.," Med. Phys. MPHYA6 0094-2405 30, 44-51 (2003). 10.1118/1.1528177 (Pubitemid 36106007)
55. P. Papagiannis, A. Angelopoulos, E. Pantelis, L. Sakelliou, D. Baltas, P. Karaiskos, P. Sandilos, and L. Vlachos, " Dosimetry comparison of I 192 r sources.," Med. Phys. MPHYA6 0094-2405 29, 2239-2246 (2002). 10.1118/1.1508378 (Pubitemid 35204431)
56. D. R. Schaart, M. C. Clarijs, and A. J. J. Bos, " On the applicability of the AAPM TG-60/TG-43 dose calculation formalism to intravascular line sources: Proposal for an adapted formalism.," Med. Phys. MPHYA6 0094-2405 28, 638-653 (2001). 10.1118/1.1357458 (Pubitemid 32323316)
57. C. G. Soares, D. G. Halpern, and C. -K. Wang, " Calibration and characterization of beta-particle sources for intravascular brachytherapy., " Med. Phys. MPHYA6 0094-2405 25, 339-346 (1998). 10.1118/1.598204 (Pubitemid 28146390)
58. J. Asenjo, J. M. Fernández-Varea, A. Sánchez-Reyes, and C. -K. Wang, " Radial dose function of a S 90 r- Y 90 seed in water and A150: Comment on Calibration and characterization of beta-particle sources for intravascular brachytherapy' [Med. Phys. 25, 339-346. 1998].," Med. Phys. MPHYA6 0094-2405 29, 2737-2738 (2002). 10.1118/1.1510455 (Pubitemid 35375474)
59. M. G. Stabin, M. Könijnenberg, F. F. Knapp, Jr., and R. H. Spencer, " Monte Carlo modeling of radiation dose distributions in intravascular radiation therapy.," Med. Phys. MPHYA6 0094-2405 27, 1086-1092 (2000). 10.1118/1.598973 (Pubitemid 30350019)
60. R. Wang and X. Allen Li, " A Monte Carlo calculation of dosimetric parameters of S 90 / Y 90 and I 192 r SS sources for intravascular brachytherapy.," Med. Phys. MPHYA6 0094-2405 27, 2528-2535 (2000). 10.1118/1.1319374
61. R. Wang and X. Allen Li, " Monte Carlo dose calculations of beta-emitting sources for intravascular brachytherapy: A comparison between EGS4, EGSnrc, and MCNP.," Med. Phys. MPHYA6 0094-2405 28, 134-141 (2001). 10.1118/1.1339880 (Pubitemid 32165748)
62. R. Wang and X. Allen Li, " Dose characterization in the near-source region for two high dose rate brachytherapy sources.," Med. Phys. MPHYA6 0094-2405 29, 1678-1686 (2002). 10.1118/1.1493780 (Pubitemid 35364202)
63. S. -J. Ye, E. I. Parsai, and J. J. Feldmeier, " Dosimetric characteristics of a linear array of γ or Β -emitting seeds in intravascular irradiation: Monte Carlo studies for the AAPM TG-43/60 formalism.," Med. Phys. MPHYA6 0094-2405 30, 403-414 (2003). 10.1118/1.1538229 (Pubitemid 36337107)
64. N. Yue, K. B. Roberts, S. E. Pfau, and R. Nath, " Dose distributions in bifurcated coronary vessels treated with catheter based photon and beta emitters in intravascular brachytherapy.," Med. Phys. MPHYA6 0094-2405 30, 1628-1636 (2003). 10.1118/1.1582813 (Pubitemid 36885780)
65. V. Sehgal, Z. Li, J. R. Palta, and W. E. Bolch, " Dosimetric effect of source centering and residual plaque for Β -emitting catheter based intravascular brachytherapy sources.," Med. Phys. MPHYA6 0094-2405 28, 2162-2171 (2001). 10.1118/1.1406520 (Pubitemid 32977563)
66. V. Sehgal, Z. Li, J. R. Palta, K. M. Smith, and W. E. Bolch, " Application of imaging-derived parameters to dosimetry of intravascular brachytherapy sources: Perturbation effects of residual plaque burden.," Med. Phys. MPHYA6 0094-2405 29, 1580-1589 (2002). 10.1118/1.1485053 (Pubitemid 34774591)
67. R. A. Fox and P. W. Henson, " The effect of contrast medium and balloon shape on dosimetry for arterial irradiation with R 188 e.," Med. Phys. MPHYA6 0094-2405 26, 771-776 (1999). 10.1118/1.598586 (Pubitemid 29227128)
68. X. A. Li, " Dosimetric effects of contrast media for catheter-based intravascular brachytherapy.," Med. Phys. MPHYA6 0094-2405 28, 757-763 (2001). 10.1118/1.1367279 (Pubitemid 32467253)
69. O. Chibani and X. Allen Li, " Dosimetric effects of source-offset in intravascular brachytherapy.," Med. Phys. MPHYA6 0094-2405 29, 530-537 (2002). 10.1118/1.1461373 (Pubitemid 34408766)
70. R. Wang, X. A. Li, and J. Lobdell, " Monte Carlo dose characterization of a new S 90 r/ Y 90 source with balloon for intravascular brachytherapy.," Med. Phys. MPHYA6 0094-2405 30, 27-33 (2003). 10.1118/1.1527673 (Pubitemid 36106004)
71. M. J. Rivard, H. D. Zinkin, J. E. Mignano, and C. D. Kimmelstiel, " Treatment of in-stent restenosis for saphenous vein grafts using intravascular brachytherapy: Regulatory challenges and clinical application.," J. Invasive Cardiol. 16, 96-98 (2004). 1042-3931
72. J. E. Mignano and M. J. Rivard, " Intravascular brachytherapy using S 90 r for saphenous vein grafts having diameters ranging from 2.0-5.0 mm.," Brachytherapy BRACC4 1538-4721 3, 173-178 (2004). 10.1016/j.brachy.2004.05.004 (Pubitemid 39472683)
73. F. Weichert, H. Müller, U. Quast, A. Kraushaar, P. Spilles, M. Heintz, C. Wilke, C. von Birgelen, R. Erbel, and D. Wegener, " Virtual 3D IVUS vessel model for intravascular brachytherapy planning I: 3D segmentation, reconstruction, and visualization of coronary artery architecture and orientation.," Med. Phys. MPHYA6 0094-2405 30, 2530-2536 (2003). 10.1118/1.1603964 (Pubitemid 37129759)
74. I. Iftimia, P. M. Devlin, L. M. Chin, J. M. Baron, and R. A. Cormack, " GAF film dosimetry of a tandem positioned b-emitting intravascular brachytherapy source train.," Med. Phys. MPHYA6 0094-2405 30, 1004-1012 (2003). 10.1118/1.1573206 (Pubitemid 36735964)
75. M. M. Miften, S. K. Das, T. D. Shafman, and L. B. Marks, " Optimization of a S 90 r/ Y 90 radiation source train stepping for intravascular brachytherapy.," Med. Phys. MPHYA6 0094-2405 29, 2891-2896 (2002). 10.1118/1.1524169 (Pubitemid 36008485)
76. P. M. Ortego, C. Prieto, and E. Vano, " Monte Carlo parametric study of stent impact on dose for catheter-based intravascular brachytherapy with S 90 r/ Y 90.," Med. Phys. MPHYA6 0094-2405 31, 1964-1971 (2004). 10.1118/1.1753431 (Pubitemid 38924815)
77. S. A. Wallace, W. Schumer, and M. Horrigan, " Monte Carlo dosimetry of a tandem positioned beta-emitting intravascular brachytherapy source train.," Med. Phys. MPHYA6 0094-2405 29, 544-549 (2002). 10.1118/1.1461845 (Pubitemid 34408768)
78. R. A. Fox, " Intravascular brachytherapy of the coronary arteries.," Phys. Med. Biol. PHMBA7 0031-9155 47, R1-R30 (2002). 10.1088/0031-9155/47/4/201 (Pubitemid 34232652)
79. I. A. Brezovich, R. A. Popple, J. Duan, S. Shen, and P. N. Pareek, " Assaying I 192 r line sources using a standard length well chamber.," Med. Phys. MPHYA6 0094-2405 29, 2692-2697 (2002). 10.1118/1.1517046 (Pubitemid 35375469)
80. B. Thomadsen, L. DeWerd, T. McNutt, S. DeWerd, and D. Schmidt, " Assessment of the strength of individual I 192 r seeds in ribbons.," Med. Phys. MPHYA6 0094-2405 26, 2471-2475 (1999). 10.1118/1.598766
81. A. Chakri and B. Thomadsen, " A quality management program for intravascular brachytherapy.," Med. Phys. MPHYA6 0094-2405 29, 2850-2860 (2002). 10.1118/1.1524167 (Pubitemid 36008481)
82. See http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cftopic/pma/pma. cfm?num=H980006 for TheraSphere's clearance (last accessed 3 November 2009).
83. See http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfTopic/pma/pma. cfm?num=p990065 for SIR-Spheres clearance (last accessed 3 November 2009).
84. See http://www.nrc.gov/materials/miau/med-use-toolkit.html for TheraSphere and SIRSpheres Yttrium-90 Microspheres, September 2008 (last accessed 13 November 2009).
85. See http://www.fda.gov/cdrh/databases.html.24 for FDA Medical Device Database. August 2008 (last accessed 3 November 2009).
86. Shalek and Gooden, Medical Physicists and Malpractice (Medical Physics Publishing, Madison, 1996).